AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18702951 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (3-month program)
Number of subjects: 27
Study 15755330 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach facilitation intervention
Number of subjects: 90283
Study 11977431 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evoked potential (VEP) during acute attack
Number of subjects: 25
Study 11977431 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked potential (BAEP) during acute attack
Number of subjects: 25
Study 11977431 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evoked potential (VEP) after 7 days post-attack
Number of subjects: 25
Study 11977431 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem auditory evoked potential (BAEP) after 7 days post-attack
Number of subjects: 25
Study 10584050 — intervention group
Group type: EXPERIMENTAL
Intervention: (15)NH(4)Cl (3.45 mg (15)N*kg(‐)(1)*d(‐)(1))
Number of subjects: 13
Study 10584050 — intervention group
Group type: COMPARATOR
Intervention: [(15)N(2)]urea
Number of subjects: 13
Study 10584050 — intervention group
Group type: EXPERIMENTAL
Intervention: (15)NH(4)Cl (3.9 mg (15)N*kg(‐)(1)*d(‐)(1))
Number of subjects: 13
Study 8902367 — intervention group
Group type: EXPERIMENTAL
Intervention: DSP-based multichannel EMG acquisition and analysis system
Number of subjects: 0
Study 8902367 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity meter for monitoring muscle activity
Number of subjects: 0
Study 8902367 — intervention group
Group type: EXPERIMENTAL
Intervention: Software for system initialization and data processing
Number of subjects: 0
Study 1808500 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (9 g daily) in group I
Number of subjects: 28
Study 1808500 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (2.4 g daily) in group II
Number of subjects: 28
Study 1808500 — intervention group
Group type: COMPARATOR
Intervention: Placebo in both groups
Number of subjects: 28
Study 6481927 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider continuity
Number of subjects: 776
Study 6481927 — intervention group
Group type: COMPARATOR
Intervention: Provider discontinuity
Number of subjects: 776
Study 31256435 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measures model
Number of subjects: 0
Study 31256435 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted repeated measures model with weights from K-means clustering
Number of subjects: 0
Study 31256435 — intervention group
Group type: COMPARATOR
Intervention: Score tests with one, two, and three degrees of freedom
Number of subjects: 0
Study 27794135 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0
Study 27794135 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 26854416 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Contrast Formula (PSCF) combined with Exponentially Decelerated Contrast Media (EDCM)
Number of subjects: 200
Study 24989702 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (HS; 300-350 mmol/day)
Number of subjects: 30
Study 24989702 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (LS; 20 mmol/day)
Number of subjects: 30
Study 22544010 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 91
Study 22544010 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 91
Study 22544010 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone
Number of subjects: 91
Study 20353859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal padded aluminum splint
Number of subjects: 87
Study 20353859 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar padded aluminum splint
Number of subjects: 87
Study 20353859 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom thermoplastic splint
Number of subjects: 87
Study 20353859 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific splint type)
Number of subjects: 87
Study 17683107 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic responsiveness
Number of subjects: 318
Study 17683107 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy
Number of subjects: 318
Study 16135859 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1-6 mg per day)
Number of subjects: 290
Study 16135859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 11840417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy agents (gemcitabine, topotecan, liposomal doxorubicin, prolonged oral etoposide) with platinum
Number of subjects: 0
Study 11840417 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 0
Study 10463522 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 421
Study 10463522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 8527263 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 10
Study 8527263 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 10
Study 8527263 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg
Number of subjects: 10
Study 8527263 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg
Number of subjects: 10
Study 2219256 — intervention group
Group type: EXPERIMENTAL
Intervention: Incubated platelet concentrates (PCs) at 37 degrees C for 1 hour
Number of subjects: 15
Study 2219256 — intervention group
Group type: COMPARATOR
Intervention: Non-incubated platelet concentrates (PCs) at 22 degrees C for 1 hour
Number of subjects: 15
Study 877527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 80
Study 877527 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 30832617 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib combined with temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) for 6 weeks, followed by Olaparib as a single agent for 4 weeks during the radiotherapy period.
Number of subjects: 79
Study 30832617 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib combined with adjuvant TMZ during the maintenance period.
Number of subjects: 79
Study 29179649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 100 million allo-hMSCs
Number of subjects: 0
Study 29179649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 200 million allo-hMSCs
Number of subjects: 0
Study 29179649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26309226 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 903
Study 26309226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 903
Study 26309226 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 903
Study 26309226 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 903
Study 26309226 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable viral load
Number of subjects: 903
Study 23550906 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg UPA
Number of subjects: 32
Study 23550906 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg UPA
Number of subjects: 32
Study 23550906 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg UPA
Number of subjects: 32
Study 23550906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21717895 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic soft tissue expander implanted in the experimental group (10 patients).
Number of subjects: 20
Study 21717895 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulated bone graft protected by titanium mesh and collagen membrane in the experimental group.
Number of subjects: 20
Study 21717895 — intervention group
Group type: COMPARATOR
Intervention: Bone block graft from anterior ramus in the reference group (10 patients).
Number of subjects: 20
Study 19470552 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation superimposed on progressive resistance training
Number of subjects: 32
Study 19470552 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation superimposed on progressive resistance training
Number of subjects: 32
Study 17295589 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to alcohol-related words
Number of subjects: 0
Study 17295589 — intervention group
Group type: COMPARATOR
Intervention: Exposure to nonalcoholic beverage words
Number of subjects: 0
Study 15117982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg, intramuscular injection, once monthly)
Number of subjects: 587
Study 15117982 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg, orally, once daily)
Number of subjects: 587
Study 15117982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg, intramuscular injection, once monthly) in ER+/PgR+ subgroup
Number of subjects: 587
Study 15117982 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg, orally, once daily) in ER+/PgR+ subgroup
Number of subjects: 587
Study 11694699 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro before breakfast
Number of subjects: 61
Study 11694699 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro before dinner
Number of subjects: 61
Study 11694699 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro after meals
Number of subjects: 61
Study 11694699 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin before meals
Number of subjects: 61
Study 9645801 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 503
Study 9645801 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 503
Study 9645801 — intervention group
Group type: COMPARATOR
Intervention: AZA
Number of subjects: 503
Study 8198411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (500 mg/kg)
Number of subjects: 67
Study 8198411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 67
Study 8198411 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 infants without suspicion of infection)
Number of subjects: 67
Study 2898256 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118,551, 50 mg orally given thrice daily
Number of subjects: 0
Study 2898256 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31852021 — intervention group
Group type: EXPERIMENTAL
Intervention: PERANTARA (self-help intervention)
Number of subjects: 132
Study 31852021 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 132
Study 29651872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates intervention for 12 weeks
Number of subjects: 64
Study 29651872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study 28912210 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 15828
Study 28912210 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptom frequency
Number of subjects: 15828
Study 28912210 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress levels
Number of subjects: 15828
Study 28912210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadness or depression levels
Number of subjects: 15828
Study 28912210 — intervention group
Group type: COMPARATOR
Intervention: Use of evidence-based medications
Number of subjects: 15828
Study 28912210 — intervention group
Group type: COMPARATOR
Intervention: Event rates for all outcomes analyzed
Number of subjects: 15828
Study 26215748 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-hour multidisciplinary vocational rehabilitation
Number of subjects: 0
Study 26215748 — intervention group
Group type: COMPARATOR
Intervention: 100-hour multidisciplinary vocational rehabilitation
Number of subjects: 0
Study 23621289 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeds 80 mL/kg/day started within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day, no intravenous fluids
Number of subjects: 46
Study 23621289 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluids 50 mL/kg/day started along with enteral feeds 30 mL/kg/day within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day
Number of subjects: 46
Study 21073773 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 81
Study 21073773 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 81
Study 18394169 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1434
Study 18394169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 1434
Study 18394169 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 1434
Study 18394169 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (ASAQ)
Number of subjects: 1434
Study 18394169 — intervention group
Group type: COMPARATOR
Intervention: Control group (Chloroquine)
Number of subjects: 1434
Study 16404409 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-specific definitions of Metabolic Syndrome (MS)
Number of subjects: 99
Study 16404409 — intervention group
Group type: COMPARATOR
Intervention: Adult definitions of Metabolic Syndrome (MS)
Number of subjects: 99
Study 16404409 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin quartiles
Number of subjects: 99
Study 14504182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin dose ≤100 mg
Number of subjects: 12562
Study 14504182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin dose 101-199 mg
Number of subjects: 12562
Study 14504182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin dose ≥200 mg
Number of subjects: 12562
Study 14504182 — intervention group
Group type: COMPARATOR
Intervention: Placebo with aspirin dose ≤100 mg
Number of subjects: 12562
Study 14504182 — intervention group
Group type: COMPARATOR
Intervention: Placebo with aspirin dose 101-199 mg
Number of subjects: 12562
Study 14504182 — intervention group
Group type: COMPARATOR
Intervention: Placebo with aspirin dose ≥200 mg
Number of subjects: 12562
Study 11778260 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 68
Study 11778260 — intervention group
Group type: COMPARATOR
Intervention: Usual care (NON-SSD)
Number of subjects: 68
Study 8962903 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutritional support supplement (1680 calories, 294 grams of carbohydrates, 36.9 grams of fat, 43.5 grams of protein in branched chain amino acids)
Number of subjects: 38
Study 8962903 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutritional support supplement
Number of subjects: 38
Study 1463361 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course DEC treatment (6, 7, 8, 9 or 10 mg kg‐1 b.w. divided into three doses daily for seven days)
Number of subjects: 1015
Study 1463361 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course DEC treatment (15 mg kg‐1 b.w. once daily for one, two or three days)
Number of subjects: 1015
Study 1463361 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC treatment for Brugia malayi infections
Number of subjects: 1015
Study 1463361 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC treatment for mixed infections
Number of subjects: 1015
Study 1463361 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC treatment for Wuchereria bancrofti infections
Number of subjects: 1015
Study 1463361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 1015
Study 6738373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol
Number of subjects: 72
Study 6738373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 31012786 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (R3R)
Number of subjects: 15459
Study 31012786 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (R3C)
Number of subjects: 15459
Study 31012786 — intervention group
Group type: COMPARATOR
Intervention: Non-malaria control vaccine (C3C)
Number of subjects: 15459
Study 31012786 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 15459
Study 31012786 — intervention group
Group type: COMPARATOR
Intervention: Non-malaria control vaccine
Number of subjects: 15459
Study 29315079 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine supplementation (1.2 mg/day)
Number of subjects: 30
Study 29315079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26573151 — intervention group
Group type: EXPERIMENTAL
Intervention: Wise Nurse educational software
Number of subjects: 37
Study 26573151 — intervention group
Group type: COMPARATOR
Intervention: Printed clinical cases (comparison group)
Number of subjects: 37
Study 25218293 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX196 (0.2, 0.4, and 2.0μg)
Number of subjects: 44
Study 25218293 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX196 with HBs antigen
Number of subjects: 44
Study 25218293 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX196
Number of subjects: 44
Study 21610154 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 889
Study 21610154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study 19596163 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol, 1 mug/d for 6 months
Number of subjects: 61
Study 19596163 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 61
Study 17617289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine capsule (4 mg)
Number of subjects: 18
Study 17617289 — intervention group
Group type: COMPARATOR
Intervention: Tizanidine tablet (reference)
Number of subjects: 18
Study 17617289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine capsule and tablet
Number of subjects: 18
Study 15767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 0
Study 15767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 0
Study 15767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 0
Study 15767241 — intervention group
Group type: COMPARATOR
Intervention: Other statins (atorvastatin, simvastatin, pravastatin)
Number of subjects: 0
Study 15767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 12231416 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral clodronate
Number of subjects: 31
Study 12231416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg oral clodronate
Number of subjects: 31
Study 12231416 — intervention group
Group type: COMPARATOR
Intervention: 30 mg intravenous clodronate
Number of subjects: 31
Study 10083698 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice at the end of the ED consultation to return to their GP for a smear (intervention)
Number of subjects: 217
Study 10083698 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 217
Study 10150325 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (120 mg/d orally)
Number of subjects: 21
Study 10150325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/d orally)
Number of subjects: 21
Study 2039377 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisone therapy (1.5 mg/kg per day and 0.75 mg/kg per day)
Number of subjects: 102
Study 2039377 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day prednisone therapy
Number of subjects: 102
Study 2039377 — intervention group
Group type: COMPARATOR
Intervention: Daily prednisone therapy
Number of subjects: 102
Study 7434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization for urinary drainage in patients with incomplete lesions
Number of subjects: 515
Study 7434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheterization for urinary drainage in patients with complete lesions
Number of subjects: 515
Study 7434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous suprapubic Bonnano (stab) continuous catheter drainage in a random group of 24 male patients with complete neurological lesions
Number of subjects: 515
Study 7434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder outlet operations
Number of subjects: 515
Study 7434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent urinary diversion
Number of subjects: 515
Study 7434114 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic and videoradiological techniques
Number of subjects: 515
Study 31090551 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program (in-hospital high-intensity endurance and strength training, high-protein nutrition and supplements, smoking cessation, psychological support)
Number of subjects: 50
Study 31090551 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 50
Study 28071141 — intervention group
Group type: EXPERIMENTAL
Intervention: CHoBI7 intervention (1-week handwashing with soap and water treatment)
Number of subjects: 344
Study 28071141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 344
Study 26842115 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 177
Study 26842115 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 177
Study 26842115 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pacing-induced DYS
Number of subjects: 177
Study 24158335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdentures (IOD)
Number of subjects: 255
Study 24158335 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures (CD)
Number of subjects: 255
Study 21130593 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose thiamine therapy
Number of subjects: 60
Study 21130593 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study 21130593 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 60